Researchers to test novel drug combination against toughest breast cancers

August 27, 2018, University of California - San Diego
Researchers to test novel drug combination against toughest breast cancers
Three-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Credit: National Institutes of Health

Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.

Cirmtuzumab is a novel monoclonal antibody developed at UC San Diego, with support from the California Institute for Regenerative Medicine (CIRM) and the CIRM-funded Alpha Clinic at UC San Diego. It targets ROR1, a cell surface protein that is present on tumors, but not in normal adult tissues, making it "a vital opportunity for targeting " said Catriona Jamieson, MD, Ph.D., Alpha Clinic director who also directs stem cell research at UC San Diego Moores Cancer Center.

Originally developed by Thomas Kipps, MD, Ph.D., Distinguished Professor of Medicine and deputy director of research at Moores Cancer Center, and colleagues as a potential treatment for chronic lymphocytic leukemia (CLL), cirmtuzumab is currently being considered and tested for other cancers as well.

Breast cancer (in women and men) is the most common type of malignancy, with almost 270,000 new cases diagnosed annually, and an estimated 41,000 deaths each year. CLL is the most common form of blood cancer in adults, accounting for roughly one quarter of new cases of leukemia (21,000) and roughly 4,500 deaths each year.

The phase I trial in will recruit up to 15 eligible participants who will undergo combination therapy for six months. Cirmtuzumab will be combined with paclitaxel (brand name: Taxol), a chemotherapy medication originally derived from the Pacific yew tree and effective in treating a several types of cancer.

Earlier this year, researchers at UC San Diego School of Medicine launched a phase Ib/II clinical trial to evaluate the combined effectiveness of cirmtuzumab with ibrutinib, a small molecule drug that inhibits Bruton's tyrosine kinase, a protein that promotes cancer cell survival and growth. Ibrutinib, marketed as Imbruvica, is already approved to treat B-cell cancers, such as CLL and mantle cell lymphoma (MCL). The combination phase Ib/II trial, sponsored by CIRM and Oncternal Inc, is actively accruing patients with CLL and MCL. (Oncternal is also one of the co-sponsors of the breast cancer trial.)

"Although ibrutinib is standard of care for patients with CLL or MCL, it is exceptionally rare for the drug by itself to completely eradicate all leukemia or produce long-lasting remissions in CLL without continuous therapy," said Kipps, who began investigating ROR1 as a cancer target in 2004.

"As a result, patients typically need to take ibrutinib indefinitely, or until they develop intolerance or resistance to this drug. Cirmtuzumab targets leukemia and cancer stem cells, which are like the seeds of cancer. They are hard to find and difficult to destroy. By blocking signaling pathways that promote cancer growth and survival, cirmtuzumab may have complementary activity with ibrutinib in killing leukemia cells, allowing patients potentially to achieve complete remissions that permit patients to stop therapy altogether."

Barbara Parker, MD, professor of medicine, breast oncologist and senior deputy director of cancer medicine at Moores Cancer Center at UC San Diego Health, said the goal in the new breast cancer trial is similar: to see if cirmtuzumab combined with paclitaxel can more fully and effectively eradicate tumors and cancer stem cells, reducing the possibility of recurrence.

"Our primary objective, of course, is to determine whether the drug combination is safe and tolerable and to measure its anti-tumor activity," said Parker. "If it proves safe and shows effectiveness against breast , we can progress to subsequent trials to determine how best to use the drug combination."

Explore further: Researchers launch combination drug trial to eradicate B-cell malignancies

Related Stories

Researchers launch combination drug trial to eradicate B-cell malignancies

March 9, 2018
Fueled by a multimillion dollar grant from the state's stem cell agency, researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have ...

Phase I trial finds experimental drug safe in treating chronic lymphocytic leukemia

June 1, 2018
Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, ...

Novel drug targeting leukemia cells enters clinical trial

September 16, 2014
Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia ...

Clinical trial to test safety of drug targeting leukemia cells

September 3, 2014
Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine (CIRM) and Celgene Corporation, a New Jersey-based biopharmaceutical company, ...

Protein-protein interaction activates and fuels leukemia cell growth

December 21, 2015
Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 ...

Anti-leukemia drug may also work against ovarian cancer

November 17, 2014
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer - and likely other cancers as well, report researchers at the University of California, ...

Recommended for you

Some brain tumors may respond to immunotherapy, new study suggests

December 10, 2018
Immunotherapy has proved effective in treating a number of cancers, but brain tumors have remained stubbornly resistant. Now, a new study suggests that a slow-growing brain tumor arising in patients affected by neurofibromatosis ...

A code for reprogramming immune sentinels

December 10, 2018
For the first time, a research team at Lund University in Sweden has successfully reprogrammed mouse and human skin cells into immune cells called dendritic cells. The process is quick and effective, representing a pioneering ...

Study finds higher risk of breast cancer for women after giving birth

December 10, 2018
Younger women who have recently had a child may have a higher risk of breast cancer than their peers of the same age who do not have children, according to a large-scale analysis co-led by a University of North Carolina Lineberger ...

Researchers develop personalized medicine tool for inherited colorectal cancer syndrome

December 10, 2018
An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes ...

Study shows key enzyme linked to therapy resistance in deadly lung cancer

December 10, 2018
Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small ...

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.